新天药业(002873) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 249,758,854, a decrease of 27.54% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was CNY 41,384,036, down 12.77% year-on-year[4]. - The company reported a basic earnings per share of CNY 0.1785, a decrease of 12.71% compared to the same period last year[4]. - Total operating revenue for the period was CNY 775,665,238.78, a decrease of 10.75% compared to CNY 869,234,233.67 in the previous period[17]. - Net profit for the period was CNY 87,711,668.99, representing a decline of 16.38% from CNY 104,887,601.16 in the previous period[18]. - Basic earnings per share decreased to CNY 0.3782 from CNY 0.4523, reflecting a decline of 16.36%[19]. Cash Flow - The net cash flow from operating activities decreased by 42.53% to CNY 36,153,971 compared to the previous year[9]. - The net cash flow from operating activities for Q3 2023 was ¥36,153,971.42, a decrease from ¥62,907,793.14 in Q3 2022[21]. - Cash inflow from operating activities totaled CNY 794,177,575.88, down from CNY 836,021,385.33 in the previous period[20]. - The net cash flow from investing activities was -¥72,748,316.97, compared to -¥24,225,800.33 in the same period last year[21]. - The net cash flow from financing activities was ¥138,871,143.28, a significant improvement from -¥21,250,130.68 in Q3 2022[21]. - The total cash and cash equivalents at the end of Q3 2023 reached ¥202,944,468.08, compared to ¥89,909,959.56 at the end of Q3 2022[21]. - The net increase in cash and cash equivalents for Q3 2023 was ¥102,276,921.10, compared to ¥17,431,862.13 in Q3 2022[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,072,090,076, representing a 12.64% increase from the beginning of the year[4]. - Total current assets as of September 30, 2023, amount to 774,113,557.58 RMB, an increase from 610,646,546.85 RMB at the beginning of the year[15]. - Total current liabilities increased to 618,619,675.86 RMB from 501,690,805.01 RMB[15]. - Total liabilities increased to CNY 876,665,072.86, compared to CNY 717,585,027.92 in the previous period, marking a rise of 22.16%[18]. - Total equity attributable to shareholders increased by 6.55% to CNY 1,195,425,003[4]. - Total equity attributable to shareholders reached CNY 1,195,425,003.44, an increase from CNY 1,121,932,356.87 in the previous period[18]. Research and Development - Research and development expenses increased by 82.29% to CNY 22,916,119, reflecting a significant rise in investment in R&D[7]. - Research and development expenses increased to CNY 22,916,119.46, up 82.00% from CNY 12,571,577.53 in the previous period[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 23.311 million[11]. - The largest shareholder, Shanghai Xintian Zhi Pharmaceutical Biotechnology Co., holds 33.55% of shares, totaling 77,763,666 shares[11]. Tax and Financial Expenses - The company experienced a 183.54% increase in taxes payable, amounting to CNY 25,148,879, attributed to higher VAT and corporate income tax[7]. - The company reported a financial expense of CNY 11,066,954.34, significantly higher than CNY 4,736,682.61 in the previous period[18]. Investment Activities - The company recorded a net loss from investment activities of CNY 72,748,316, a significant increase of 200.29% compared to the previous year[9]. - The company reported a total cash inflow from investment activities of ¥1,000.16 in Q3 2023, down from ¥135,861,764.27 in Q3 2022[21]. - The cash outflow for purchasing fixed assets and intangible assets was ¥72,748,317.13 in Q3 2023, compared to ¥105,087,564.60 in Q3 2022[21]. Other Information - The company has not reported any new strategies or product developments in the current quarter[13]. - The company did not conduct an audit for the Q3 2023 report[22].